Ebos Group (ASX:EBO) Research & Development: A$0 Mil (TTM As of Dec. 2025)


ASX:EBO Ebos Group Ltd ASX:EBO
77 GF Score
Price A$16.76
GF Value A$31.49
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ebos Group Research & Development?

Ebos Group ASX:EBO +0.30% 77 Research & Development is A$0 Mil as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$31.49 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ebos Group's Research & Development for the six months ended in Dec. 2025 was A$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0 Mil.

Ebos Group  (ASX:EBO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ebos Group Research & Development Related Terms

Ebos Group Research & Development Historical Data

* Premium members only.

The historical data trend for Ebos Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group Research & Development Chart

Ebos Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ebos Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:EBO
77GF Score
Ebos Group Ltd ASX:EBO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ebos Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0 Mil mean?
Ebos Group (ASX:EBO) has a Research & Development of A$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Ebos Group and its competitors.
Is Ebos Group's Research & Development too high?
Ebos Group's current Research & Development is A$0 Mil. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Research & Development compare to MCK and COR?
Ebos Group's Research & Development of A$0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ebos Group and its competitors. Ebos Group's current Research & Development is A$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.49, compared to a current price of A$16.76 — trading 46.8% below its estimated fair value. The current Research & Development is A$0 Mil. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Research & Development is A$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (ASX:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of A$16.76 is trading 46.8% below its estimated GF Value™ of A$31.49. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for ASX:EBO:

  • Research & Development: A$0 Mil
  • GF Value™: A$31.49 vs. price of A$16.76 (46.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score

Get the complete analysis for ASX:EBO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$16.76
Price
A$31.49
GF Value